Short Interest in Dynavax Technologies Co. (NASDAQ:DVAX … – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 13,820,000 shares, a decrease of 12.1% from the November 15th total of 15,730,000 shares. Based on an average trading volume of 1,880,000 shares, the days-to-cover ratio is currently 7.4 days.

Insider Transactions at Dynavax Technologies

In other news, COO David F. Novack sold 52,204 shares of the company’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $12.47, for a total transaction of $650,983.88. Following the completion of the sale, the chief operating officer now owns 2,066 shares in the company, valued at approximately $25,763.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, COO David F. Novack sold 52,204 shares of the business’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $12.47, for a total transaction of $650,983.88. Following the completion of the transaction, the chief operating officer now owns 2,066 shares of the company’s stock, valued at approximately $25,763.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew A. F. Hack sold 1,500,000 shares of the business’s stock in a transaction dated Tuesday, December 6th. The stock was sold at an average price of $11.60, for a total value of $17,400,000.00. Following the transaction, the director now directly owns 3,915,000 shares of the company’s stock, valued at approximately $45,414,000. The disclosure for this sale can be found here. 9.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dynavax Technologies

Large investors have recently modified their holdings of the stock. Advisors Asset Management Inc. grew its position in Dynavax Technologies by 498.0% during the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 1,967 shares during the last quarter. Quantbot Technologies LP grew its position in Dynavax Technologies by 940.7% during the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 2,267 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in Dynavax Technologies during the 2nd quarter worth approximately $67,000. Creative Financial Designs Inc. ADV grew its position in Dynavax Technologies by 1,875.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 7,900 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 7,500 shares during the last quarter. Finally, KBC Group NV bought a new stake in Dynavax Technologies during the 3rd quarter worth approximately $100,000. 96.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DVAX shares. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $24.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, November 4th. TheStreet cut Dynavax Technologies from a “b-” rating to a “c+” rating in a report on Thursday, September 1st. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Monday, November 7th. Finally, JMP Securities initiated coverage on Dynavax Technologies in a report on Tuesday, September 27th. They issued an “outperform” rating and a $22.00 price target for the company. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Trading Up 0.2 %

DVAX stock opened at $11.17 on Friday. Dynavax Technologies has a 1-year low of $7.26 and a 1-year high of $17.48. The firm has a market cap of $1.43 billion, a P/E ratio of 5.40 and a beta of 1.34. The business’s 50 day moving average is $11.83 and its 200-day moving average is $12.32. The company has a current ratio of 3.82, a quick ratio of 3.40 and a debt-to-equity ratio of 0.44.
Dynavax Technologies (NASDAQ:DVAX – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.10. Dynavax Technologies had a return on equity of 90.54% and a net margin of 44.35%. The company had revenue of $167.74 million for the quarter, compared to analyst estimates of $149.99 million. Equities analysts anticipate that Dynavax Technologies will post 1.84 earnings per share for the current fiscal year.

About Dynavax Technologies

(Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dynavax Technologies wasn’t on the list.
While Dynavax Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source